CN1129955A - 截短的生物活性更高的角质形成细胞生长因子 - Google Patents

截短的生物活性更高的角质形成细胞生长因子 Download PDF

Info

Publication number
CN1129955A
CN1129955A CN94193193A CN94193193A CN1129955A CN 1129955 A CN1129955 A CN 1129955A CN 94193193 A CN94193193 A CN 94193193A CN 94193193 A CN94193193 A CN 94193193A CN 1129955 A CN1129955 A CN 1129955A
Authority
CN
China
Prior art keywords
growth factor
sequence
keratinocyte growth
cell
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94193193A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·戈斯波达罗维茨
F·马西阿茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1129955A publication Critical patent/CN1129955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN94193193A 1993-06-29 1994-04-28 截短的生物活性更高的角质形成细胞生长因子 Pending CN1129955A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
US08/086,427 1993-06-29

Publications (1)

Publication Number Publication Date
CN1129955A true CN1129955A (zh) 1996-08-28

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94193193A Pending CN1129955A (zh) 1993-06-29 1994-04-28 截短的生物活性更高的角质形成细胞生长因子

Country Status (25)

Country Link
US (7) US5677278A (ja)
EP (2) EP1493812A3 (ja)
JP (4) JP3570516B2 (ja)
KR (1) KR960703433A (ja)
CN (1) CN1129955A (ja)
AT (1) ATE278777T1 (ja)
AU (1) AU681405B2 (ja)
BG (1) BG100236A (ja)
BR (1) BR9407035A (ja)
CA (1) CA2166278A1 (ja)
CZ (1) CZ343795A3 (ja)
DE (2) DE69434053T2 (ja)
DK (1) DK0706563T3 (ja)
ES (1) ES2227527T3 (ja)
FI (1) FI956203A (ja)
FR (1) FR06C0004I2 (ja)
HU (1) HUT73453A (ja)
LU (1) LU91215I2 (ja)
NL (1) NL300217I2 (ja)
NO (1) NO955189D0 (ja)
NZ (1) NZ266622A (ja)
PL (1) PL312257A1 (ja)
PT (1) PT706563E (ja)
SK (1) SK153295A3 (ja)
WO (1) WO1995001434A1 (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (en) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (es) * 1994-10-13 2004-01-16 Amgen Inc. Metodo para purificar factores de crecimiento de queratinocitos.
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
CA2202075C (en) * 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
JP2001506975A (ja) * 1996-10-15 2001-05-29 アムジェン インコーポレイテッド ケラチノサイト増殖因子―２産物
EP1003770A4 (en) * 1997-06-19 2002-10-30 Inst Genetics Llc SECRETIED POLYPEPTIDES AND THESE ENCODING POLYNUCLEOTIDES
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
US6485937B1 (en) 1999-10-15 2002-11-26 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
WO2002077155A2 (en) * 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Keratinocyte growth factor-2
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7265089B2 (en) 2001-08-21 2007-09-04 Chiron Corporation KGF polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
SI1827483T1 (sl) * 2004-12-15 2014-11-28 Swedish Orphan Biovitrum Ab (Publ) Terapevtske formulacije keratinocitnega rastnega faktorja
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
AU2022336409A1 (en) 2021-08-30 2024-02-15 Unichem Laboratories Limited Protein compositions for the treatment of inflammatory diseases
KR20230070596A (ko) * 2021-11-15 2023-05-23 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (en) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) * 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
CA2202390C (en) 1994-10-13 2005-05-17 Bao-Lu Chen Keratinocyte growth factor analogs
CA2202075C (en) 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using

Also Published As

Publication number Publication date
NZ266622A (en) 1997-10-24
US5843883A (en) 1998-12-01
JP3570516B2 (ja) 2004-09-29
WO1995001434A1 (en) 1995-01-12
JP2006075173A (ja) 2006-03-23
US6677301B1 (en) 2004-01-13
US5863767A (en) 1999-01-26
FR06C0004I2 (fr) 2006-12-29
JP2009062396A (ja) 2009-03-26
DK0706563T3 (da) 2005-01-31
ATE278777T1 (de) 2004-10-15
BG100236A (en) 1996-07-31
KR960703433A (ko) 1996-08-17
DE122006000005I2 (de) 2006-11-23
DE69434053D1 (de) 2005-01-20
EP1493812A2 (en) 2005-01-05
FI956203A0 (fi) 1995-12-22
JP4662569B2 (ja) 2011-03-30
BR9407035A (pt) 1996-03-12
NL300217I2 (nl) 2006-05-01
JP2004166709A (ja) 2004-06-17
CZ343795A3 (en) 1996-07-17
US20090093400A1 (en) 2009-04-09
ES2227527T3 (es) 2005-04-01
NO955189L (no) 1995-12-20
FI956203A (fi) 1996-02-07
JPH09500267A (ja) 1997-01-14
US5677278A (en) 1997-10-14
EP1493812A3 (en) 2006-02-08
EP0706563B1 (en) 2004-10-06
US5773586A (en) 1998-06-30
HUT73453A (en) 1996-08-28
PL312257A1 (en) 1996-04-01
NO955189D0 (no) 1995-12-20
CA2166278A1 (en) 1995-01-12
AU681405B2 (en) 1997-08-28
PT706563E (pt) 2005-01-31
EP0706563A1 (en) 1996-04-17
FR06C0004I1 (ja) 2006-03-10
DE122006000005I1 (de) 2006-08-10
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
US6074848A (en) 2000-06-13
LU91215I2 (en) 2006-03-27
DE69434053T2 (de) 2006-02-23
SK153295A3 (en) 1996-11-06
HU9503857D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
CN1129955A (zh) 截短的生物活性更高的角质形成细胞生长因子
US7803602B2 (en) Method for overexpression of zwitterionic polysaccharides
JP4271952B2 (ja) ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
CN1052263C (zh) 热稳定性胞嘧啶脱氨酶
CN1038126A (zh) 双边条曲菌素：一种新型的双功能生长调节糖蛋白
CN1214050A (zh) 人肿瘤坏死因子δ和ε
JP2006055168A (ja) ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
CN1299407A (zh) 血管内皮生长因子2
CN1233415C (zh) Cd26/dpp iv在制备治疗和/或诊断疾病的药物中的应用
CN1190991A (zh) 人类趋化因子β－11和人类趋化因子α－1
CN1217024A (zh) 趋化因子α－2
CN1240001A (zh) 链球菌毒素c突变体及其使用方法
CN1192751A (zh) 单核细胞趋化蛋白－4
US6472509B1 (en) Feline cytokine protein
CN1131309C (zh) 白细胞介素－6突变蛋白
CN1431306A (zh) 人类肝癌衍生生长因子5、其编码序列、制法及用途
CN1287170A (zh) 一种新的人神经递质运输蛋白及其编码序列
CN1287169A (zh) 新的人g蛋白亚基及其编码序列
CN1303940A (zh) 人夏科－莱登晶体2及其编码序列、以及制法和用途
CN1183803A (zh) 成纤维细胞生长因子－14
CN1161714A (zh) 人趋化因子β-9
CN1303935A (zh) 人夏科－莱登晶体6及其编码序列,以及制法和用途
CN1252448A (zh) 人肌动蛋白相关蛋白基因、其编码的多肽及制法和用途
CN1366046A (zh) 人疾病相关表皮生长因子编码序列、其制备方法及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication